Prodotti farmaċewtiċi

This page is also available in

Displaying 1 - 10 of 25


Adottati on 27/04/2021
Sessjoni plenarja: 
560 -
Apr 27, 2021 Apr 28, 2021

The Commission proposes a new pharmaceutical strategy for Europe. It is a patient-centred strategy that aims to ensure the quality and safety of medicines, while boosting the sector’s global competitiveness. The EU needs to make sure that patients have access to high-quality, effective and safe medicines. It will foster patient access to innovative and affordable medicines. It will support the competitiveness and innovative capacity of the EU’s pharmaceutical industry.

Opinjoni tal-KESE: Pharmaceutical strategy

Adottati on 02/03/2020

Opinjoni tal-KESE: Financial aid for Member States and countries still negotiating the terms of their accession to the EU which are seriously affected by a major public health emergency


Position paper - Financial assistance to Member States affected by a major public health emergency

Adottati on 23/04/2015

Health and related sectors are a central aspect of human existence and thus attract particular attention of citizens. The sectors of biomedical engineering and the medical and care services industry – including research and development – are among the fastest growing industrial areas, in terms of turnover as well as employment. Under biomedical engineering we understand the bridging between methods of engineering and medicine and biology for diagnostic and therapeutic measures in healthcare – including, among others, biologics and biopharmaceuticals, pharmaceutical drugs, various types of devices for chemical or biological analysis or processing as well as the development of medical equipment and technology for cure, treatment and prevention of disease. The combination of research and development, engineering and industrial production, and medical and care services is particularly important.


Biomedical engineering and care services


Presentation by Prof. Stefan N. Constantinescu

Presentation by Andre Linnenbank, Secretary General of EAMBES

Presentation by Manfred Bammer, MSc, MAS | Head of Biomedical Systems

Presentation by Nicolas Gouze, General Secretary of ETP Nanomedicine

Presentation by Prof. dr. ir. Pascal Verdonck

Presentation by Ruxandra Draghia-Akli Director Health DG Research and Innovation European Commission

Adottati on 29/04/2014

Due to the increased need for cost-efficient procedures and the pressure on public expenditure, the European market for pharmaceutical products is less dynamic than in the past. This high-technology sector is faced with the following challenges: austerity measures introduced by European governments, rapid growth in the market and research in emerging economies, and migration of economic, research and development activities outside of Europe.

Industrial Changes in the European Pharmaceutical Sector